Table 1: Comparisons of anti-TNF studies in RA patients Study   No. of patients   Patient characteristics   Active treatment   Control   Response* (active treatment vs. control)   Inhibition of radiographic progression           ACR20 ACR50 ACR70   ATTRACT   428   Established RA   Infliximab 3mg/kg, 10mg/kg at 4- or 8- week intervals, along with MTX   MTX   42-59% vs. 17% 21-39% vs. 8% 10-25% vs. 2%   Yes TEMPO   682   Established RA, no recent exposure to MTX   MTX plus etanercept 25mg twice weekly   Etanercept or MTX   85% vs. 75-76% 69% vs. 43-48% 43% vs 19-24%   Yes ERA   632   Early RA   Etanercept 10mg or 25mg twice weekly   MTX   72% vs. 65% (N.S.) Not stated Not stated   Yes ARMADA   271   Established RA   Adalimumab 20, 40 or 80mg biweekly plus MTX   MTX   48-66% vs. 15% 32-43% vs. 8.1% 19-27% (40 or 80mg groups) vs. 5%   Yes                               *Comparisons were statistically significant unless otherwise stated (N.S.)